Diabetes

Tirzepatide and semaglutide show long-term health care cost savings but, the high cost of the medications offset the savings.

Among various weights and diabetes diagnoses, researchers explored the differences in patients’ food perceptions when considering weight management and appetite.

These findings challenge the common assumption that older adults might struggle to use more advance medical devices.

Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol levels could potentially be a valuable biomarker for determining the risk of diabetic kidney disease.

In a previous study, results showed that patients taking semaglutide could be at a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION), causing blindness.

The feasibility study shows that the STEADY intervention is possible for patients with type 1 diabetes and eating disorders without deteriorating glycemic control.

However, investigators did not determine the association between compatibility status and loss-of-signal alarms.

A new study found that GLP-1s were not associated with an increased risk of suicidal ideation, self-harm, or suicide compared to DPP-4 and SGLT-2 inhibitors.

Authors of a research letter published in JAMA said that the decrease in glycemic control may be due to consequences of the COVID-19 pandemic, such as sedentary behavior and increased mental health stressors.

The increased risk of symptoms only includes respiratory-related symptoms or brain fog.

The technology will be available to patients in the United States in March 2025.

Semaglutide has been in shortage since 2022 due to increased demand.

Tirzepatide (Mounjaro, Zepbound), a glucagon-like peptide-1 (GLP-1) medication, demonstrates improved diabetes control and decreases in insulin requirements.

A recent metanalysis found that patients with type 1 diabetes had a 50% higher chance of developing dementia.

By 12 weeks, investigators report that SkinTE facilitated significantly more wound closures compared with the standard of care.

Among a diverse cohort of patients with type 2 diabetes (T2D), researchers examined the use of automated insulin delivery for lowering hemoglobin A1c levels.

The drug is the first rapid-acting insulin biosimilar product approved for use by the FDA, marking a significant milestone in diabetes treatment.

Recently, there has been concern around glucagon-like peptide-1 receptor agonists and increase the risk of thyroid cancer, with liraglutide having a black box warning label for the disease.

Social media can help close the gap on health care information access, but pharmacists still play a large role in diabetes management, especially in therapeutics.

App notifications can be effected by various notification focuses, software updates, or connecting hardware, such as car audio or wireless earphones.

Children with type 1 diabetes who watched educational videos and played games had improved glycemic control and quality of life.

The therapy is now the first and only FDA-approved treatment that maintains vision with fewer treatments compared to standard-of-care injections.

Sodium-glucose cotransporter 2 inhibitors are more cardioprotective in older adults and glucagon-like peptide-1 receptor agonists for younger patients.

There is no standard way to define resilience in adolescent patients with type 1 diabetes, though many studies see resilience as an ability or process.

Patients with diabetes and prediabetes have older brain ages than their chronological age compared with normoglycemic patients.

A recent systematic review and meta-analysis found that almost half of all patients with type 2 diabetes were deficient in multiple micronutrients.

Ozempic is now the most broadly indicated glucagon-like peptide-1 receptor agonist across the pharmaceutical drug market.

Among a population of patients with type 2 diabetes, researchers assessed the similarities and differences between SGLT2 inhibitors.

Heather Folz, PharmD, BCACP and Christina H. Sherrill, PharmD, BCACP, BC-ADM discuss challenges pharmacists may face when implementing CGM services and how they can help raise awareness.

Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.